Analysis shows a 25% increase in U.S. private insurer prescription drug denials from 2016-2023, driven by rising drug costs and claim automation. Insights into industry impact and reform efforts.

Prescription drug denials by private insurers rise 25% (2016-2023). Sarepta gene therapy linked to patient deaths. ICE gains Medicaid data access. ACA insurers seek 2026 rate hikes. Implications for U.S. insurance, regulatory compliance, and patient access.

Maris Kreizman shares insights on the evolving U.S. publishing industry, freelance writing challenges, health insurance issues for creatives, and critiques of corporate media structures.

Research reveals immune checkpoint inhibitors improve cancer survival rates but widen insurance-based disparities. Expanding health coverage may mitigate gaps in treatment outcomes.

Alaska's SB 133 mandates 72-hour decision deadlines for health insurance authorizations, increases transparency, and protects patients with chronic conditions, effective 2027.

Learn how to avoid lifetime Medicare Part D penalties by timely enrollment, understanding creditable coverage, and utilizing Extra Help financial assistance programs.

Humana's legal loss against CMS over Medicare Advantage star ratings underscores structural regulatory risks reshaping insurer margins and strategies in the U.S. Medicare Advantage market.

A detailed debate on the proposal for a U.S. government health insurance plan competing with private insurers, highlighting key perspectives from experts Jacob Hacker and David Goldhill.

Kentucky's 2023 legislation enhances insurance innovation, consumer protections, and financial sector regulations, including expanded insurance sandboxes and improved health and automobile insurance standards.

Elevance Health lowers 2024 earnings guidance due to rising medical utilization, Medicaid eligibility checks resuming, and regulatory challenges impacting Medicaid and ACA programs.